Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.
about
Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.Does the Fuhrman or World Health Organization/International Society of Urological Pathology Grading System Apply to the Xp11.2 Translocation Renal Cell Carcinoma?: A 10-Year Single-Center Study.Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
P2860
Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Renal Cell Carcinoma Associate ...... res, Treatments and Prognosis.
@ast
Renal Cell Carcinoma Associate ...... res, Treatments and Prognosis.
@en
type
label
Renal Cell Carcinoma Associate ...... res, Treatments and Prognosis.
@ast
Renal Cell Carcinoma Associate ...... res, Treatments and Prognosis.
@en
prefLabel
Renal Cell Carcinoma Associate ...... res, Treatments and Prognosis.
@ast
Renal Cell Carcinoma Associate ...... res, Treatments and Prognosis.
@en
P2093
P2860
P1433
P1476
Renal Cell Carcinoma Associate ...... res, Treatments and Prognosis.
@en
P2093
Baolei Miao
Dongmei Li
Hongqian Guo
Weidong Gan
Xiancheng Chen
P2860
P304
P356
10.1371/JOURNAL.PONE.0166897
P407
P50
P577
2016-11-28T00:00:00Z